Biotech Values

[urche]

Any chance this leads to an increase treatment duration with Enoxaparin in this patient population?

I believe there is substantial evidence to support continuing DVT prophylaxis longer, to some fuzzy point well beyond acute hospitalization. The problem is defining when to stop. For many of the patients I see, it could be started in the hospital, following which it could easily be continued lifelong if risk of thromboembolism were the only consideration. In reality, there are factors such as patients not wanting injections, cost, bleeding complications and insurance coverage will limit its use.